In a landmark study published in Science Advances, researchers from Bar-Ilan University have uncovered critical insights into how antibiotic use increases the risk of inflammatory bowel disease (IBD). The study demonstrates that antibiotics disrupt the protective mucus layer in the intestine, which plays a vital role in shielding the immune…

Research led by the Icahn School of Medicine at Mount Sinai, New York, has confirmed a link between the genetics of inflammatory bowel disease (IBD) and Parkinson’s disease. The team that discovered the connection hopes their findings can help design therapies that could target both conditions. “Our research not only…

In a recent breakthrough at the University of Michigan, researchers have shed light on the interplay between diet, genetics, and the gut microbiome, offering fresh insights into the triggers of inflammatory bowel disease (IBD). IBD, characterized by symptoms such as abdominal pain, diarrhea, and weight loss, has long puzzled the…

New microbiome-based evidence suggests a two-drug combination, a blockade of both IL-22 and IL-1R, may treat inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis. This team studied “upstream cues” of microbial interactions with intestinal cells. They report that IL-22 and IL-1R can trigger “a chain reaction” that…

Researchers and clinicians from the Quadram Institute, the Earlham Institute, the Norfolk and Norwich University Hospital, and University of East Anglia, with collaborators in Cambridge, London, and Leuven, have found that patients with Inflammatory bowel disease (IBD) develop the condition due to distinct and different mechanisms, determined by their genetics.…

Using organoids derived from adult stem cells in the gut tissue of patients with Crohn’s disease, researchers from the University of California, San Diego (UCSD) have discovered that the condition consists of two distinct molecular subtypes. The discovery of these distinct molecular subtypes, published in Cell Reports Medicine, promises to…

Researchers from the Broad Institute of MIT and Harvard together with Massachusetts General Hospital investigators have identified specific species of bacteria in the gut that consume bacteria to help lower cholesterol and decrease the risk of heart disease. The research, published Tuesday in the journal Cell, adds to the list…

Research led by investigators from the University of Cambridge has shown that administration of the drug infliximab for newly-diagnosed patients of Crohn’s disease dramatically improves outcomes—including the reduction of people needing abdominal surgery for treatment by ten-fold. Results of the trial were published this week in The Lancet. Called the…

A team of international researchers, led by the University of Plymouth, has unveiled a novel technique that could pave the way for discovering and developing new therapeutics for prevalent autoimmune diseases. Reporting in Nature Biomedical Engineering, the researchers introduce the Secretion-Enabled Cell Ranking and Enrichment (SECRE) method, which promises to…

A new evidence-based guideline for use of blood- and stool-based biomarkers to help manage Crohn’s disease was released today by the American Gastroenterological Association (AGA). Crohn’s is a type of inflammatory bowel disease (IBD), a condition estimated to affect 2.74 million people in the U.S. alone. The guideline was published today in Gastroenterology. “Based on…

Direct injection of neonatal mesenchymal stem cells (MSCs) from discarded heart tissue from surgery could aid in healing Crohn’s disease, according to new research from investigators at the Ann & Robert H. Lurie Children’s Hospital of Chicago. The study, published in the journal Advanced Therapeutics, found that the technique, reduced…

Recludix Pharma has announced a strategic collaboration with Sanofi to develop and commercialize first-in-class oral small molecule STAT6 (signal transducer and activator of transcription 6) inhibitors for patients with immunological and inflammatory diseases. STAT6 is believed to play a key role in multiple dermatological and respiratory diseases. Sanofi will pay $125…

Former rare disease firm Aeglea BioTherapeutics has reinvented itself by acquiring newly minted Spyre Therapeutics, which has a pipeline of antibody therapeutics for inflammatory bowel disease (IBD). Spyre says it specializes in long-acting antibodies, rational therapeutic combinations, and precision immunology approaches. Concurrent with the stock-for-stock deal, Aeglea entered a private…

An international research consortium, led by researchers of the Wellcome Sanger Institute and the Broad Institute of MIT and Harvard, has identified 10 new genetic variants linked to an elevated risk of developing Crohn’s disease (CD). The study, published today in Nature Genetics, is the largest of its kind to…

Scientists at Cedars-Sinai and the National Institute of Allergy and Infectious Diseases (NIAID) have adopted an unconventional approach to understand the function of these gut microbes—mining the host organism’s immune memory. Ivan Vujkovic-Cvijin, Ph.D., an assistant professor in the Department of Biomedical Sciences and Gastroenterology at…